ALL-090 Highly Effective Combination of FLT3 and BCL2 Inhibitors in a Preclinical Model of Lineage Ambiguous Leukemia

Context: Lineage ambiguous leukemias are rare leukemia subtypes with diagnostic and treatment challenges and poor outcomes. We recently described a new subtype of lineage ambiguous leukemia defined by aberrant BCL11B activation (“BCL11B-a”) which included 30%–40% of T/myeloid mixed-phenotype acute l...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia Jg. 22; S. S193 - S194
Hauptverfasser:	Montefiori, Lindsey, lacobucci, Ilaria, Budhraja, Amit, Moore, Jamila, Baskin, Rebekah, DeVries, Rebekah, Backhaus, Emily, Johnson, Melissa, Akers, Walter, Chepyala, Divyabharathi, Mehr, Cyrus, Seth, Aman, Mead, Paul, Opferman, Joseph, Mullighan, Charles
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Elsevier Inc 01.10.2022
Schlagworte:	ALL BCL11B gilteritinib lineage-ambiguous MPAL venetoclax ALL lineage-ambiguous gilteritinib MPAL BCL11B venetoclax
ISSN:	2152-2650
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!